STARPHARMA-HOLDINGS-LTD
28.10.2016 05:21:29 CEST | Business Wire | Press release
Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) today announced the allowance of a patent by the US Patent Office for a Priostar® glyphosate formulation. The patent’s term is expected to be to 2030 providing an extension over existing granted Priostar® patents. Additional term may also be available in relation to patent office delay and regulatory approval.
This patent adds further value to the Priostar® patent portfolio which comprises granted patents in key markets, including in the US, Europe, and China. This patent will extend the value of the Priostar® glyphosate product opportunity for both Starpharma and its partners.
Priostar® -enhanced glyphosate formulations have been shown to deliver improved weed control capabilities compared to standard marketed formulations of glyphosate, particularly in hard to kill weeds. The enhanced formulations have also shown faster knock-down of weeds.
Glyphosate (the active ingredient in Roundup® ) is the world’s most widely used herbicide with 2014 global market sales of US$5.7B(1) and is expected to grow to US$8.8B by 2019(2) . In the United States, glyphosate is the leading herbicide for the control of weeds on maize, soybean and cotton crops, making it one of the most widely used herbicides. It is also used in agriculture and forestry, on lawns and gardens, and for weeds in industrial areas.
Starpharma has Priostar® partnerships with a number of global partners to enhance agricultural formulations, including with Adama for a Priostar® improved 2,4-D formulation for the US market.
Starpharma Chief Executive, Dr Jackie Fairley, commented: “This development for our glyphosate Priostar® patent portfolio is a valuable commercial achievement and confirmation of the innovation that Priostar® brings to crop protection products. We continue to work in partnership with leading agrochemical companies across the globe to develop innovative, proprietary Priostar® formulations that improve product performance and deliver benefits to farmers.”
(1)
Phillips McDougall Industry Overview 2015.
(2)
Transparency
Market Research 2014.
About Starpharma
Starpharma
Holdings Limited, located in Melbourne Australia, is an ASX 300 company
and is a world leader in the development of dendrimer products for
pharmaceutical, life science and other applications.
For more information please visit: www.starpharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027007030/en/
Contact:
Media:
WE Buchan
Rebecca Wilson
Mob:
+61-417-382-391
rwilson@buchanwe.com.au
or
Starpharma:
Dr
Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and
Company Secretary
+61-3-8532-2704
investor.relations@starpharma.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqara Announces the Availability of The Spatial Multi-Sensor FP400, Offering Advanced Spatial Intelligence for Smart Homes16.9.2026 09:00:00 CEST | Press release
Aqara, a global leader and pioneer in IoT, today announced the release of the Spatial Multi-Sensor FP400. The FP400 is designed to bring precise, spatial intelligence to homes without sacrificing the privacy typically compromised by smart cameras. Rather than simply detecting motion or presence, the FP400 enables homes to better understand occupancy, movement, and context for more granular and personalized automations and insight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916958372/en/ Aqara Announces the Availability of The Spatial Multi-Sensor FP400, Offering Advanced Spatial Intelligence for Smart Homes The Spatial Multi-Sensor FP400 redefines how smart homes perceive and interact with living spaces by combining high-precision spatial sensing with AI-powered environmental understanding. Powered by a next-generation high-precision 60GHz mmWave radar, the FP400 delivers industry-leading multi-person sensing, precise
Cambridge Associates Opens Italian Office and Expands European Leadership16.9.2026 09:00:00 CEST | Press release
Global investment firm Cambridge Associates (CA) today announced the opening of a new office in Milan and the appointment of two senior hires in Europe. The move reflects the firm’s ongoing commitment to providing bespoke services to current and future institutional and family office investors across the region. Raphael Heynold has joined the Client Solutions team as Head of EMEA and APAC and will serve on the firm’s EMEA Operating Committee. Based in London, Raphael is a key member of the Global Client Solutions Leadership team, responsible for driving growth and market expansion and overseeing client engagement efforts across Europe, the Middle East, and Asia Pacific regions. Heynold brings more than 30 years of experience across client strategy, investment banking and investment management, and has worked with many sophisticated families and institutions around the world. Riccardo Pianeti has joined Cambridge Associates to lead the Italian office. He will serve as Head of the Milan
International Expansion Far Outweighs M&A as a Legal and Compliance Execution Burden, CSC Research Finds16.9.2026 08:49:00 CEST | Press release
International expansion far outweighs M&A as a legal and compliance execution burden, cited by 74% of senior cross-border professionals versus 28%54% often redo work because entity or ownership information is incomplete or outdatedHalf say information gaps can add one to two weeks to cross-border work International expansion is creating a far heavier legal and compliance execution burden than M&A itself, with nearly three quarters (74%) of senior cross-border professionals citing market entry or international expansion as a leading burden, compared with just 28% for M&A transactions, according to new research from CSC, the leading provider of global business administration and compliance solutions. The challenge extends well beyond deal execution. Ongoing entity governance and compliance is cited by 71% of respondents, highlighting the operational burden of establishing and maintaining a presence across multiple jurisdictions. CSC’s new report, The Cross-Border Readiness Gap: Navigatin
Okomera Strengthens Its Leadership Team With the Appointment of Marion Ghibaudo as Chief Technology Officer16.9.2026 08:00:00 CEST | Press release
An expert in scaling medical innovations, Marion Ghibaudo joins Okomera as the company advances toward industrial deployment. Okomera, a TechBio company pioneering next-generation cancer care through the development of a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the appointment of Marion Ghibaudo as Chief Technology Officer. She will spearhead the company’s technology and innovation strategy and lead the industrial deployment of its integrated hardware, software, and biological platform. Marion Ghibaudo will join Okomera’s Executive Committee and report to CEO Silvère Lucquin. In parallel, Raphaël Tomasi, Okomera’s co-founder and former CTO, transitions to the role of VP Platform, ensuring continuity in the development of the company’s technology platform. Marion’s appointment comes at a key stage in Okomera’s growth as the company advances toward pilot studies, industrial scale-up, and commercialization. Okomer
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing16.9.2026 07:00:00 CEST | Press release
Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121 Restylane Volyme was well tolerated, with no incidences of granulomas. Patient and investigator satisfaction were also high1 These data support Galderma’s aim to expand the availability of the Restylane portfolio in China – a market undergoing significant expansion, and further strengthen Restylane’s vast clinical evidence base2,3 Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom